BR112019003673A2 - formulação farmacêutica, uso de uma formulação farmacêutica e método para evitar o aumento da viscosidade durante o armazenamento de uma formulação farmacêutica - Google Patents

formulação farmacêutica, uso de uma formulação farmacêutica e método para evitar o aumento da viscosidade durante o armazenamento de uma formulação farmacêutica

Info

Publication number
BR112019003673A2
BR112019003673A2 BR112019003673-3A BR112019003673A BR112019003673A2 BR 112019003673 A2 BR112019003673 A2 BR 112019003673A2 BR 112019003673 A BR112019003673 A BR 112019003673A BR 112019003673 A2 BR112019003673 A2 BR 112019003673A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulation
during storage
increased viscosity
viscosity during
preventing increased
Prior art date
Application number
BR112019003673-3A
Other languages
English (en)
Inventor
Sartor Franco
Pertile Marisa
Soliani Raschini Annamaria
Original Assignee
Chiesi Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.
Publication of BR112019003673A2 publication Critical patent/BR112019003673A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0082—Lung surfactant, artificial mucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Abstract

a presente invenção é direcionada a uma formulação farmacêutica física e quimicamente estável, na forma de uma suspensão aquosa que compreende um surfactante pulmonar reconstituído. tal formulação é adequada para a profilaxia e/ou tratamento de síndrome de desconforto respiratório (sdr) e outros distúrbios respiratórios.
BR112019003673-3A 2016-08-24 2017-08-09 formulação farmacêutica, uso de uma formulação farmacêutica e método para evitar o aumento da viscosidade durante o armazenamento de uma formulação farmacêutica BR112019003673A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16185516 2016-08-24
EP16185516.8 2016-08-24
PCT/EP2017/070169 WO2018036819A1 (en) 2016-08-24 2017-08-09 Stable pharmaceutical formulation comprising a reconstituted pulmonary surfactant composition

Publications (1)

Publication Number Publication Date
BR112019003673A2 true BR112019003673A2 (pt) 2019-05-21

Family

ID=56800200

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019003673-3A BR112019003673A2 (pt) 2016-08-24 2017-08-09 formulação farmacêutica, uso de uma formulação farmacêutica e método para evitar o aumento da viscosidade durante o armazenamento de uma formulação farmacêutica

Country Status (12)

Country Link
US (1) US10543256B2 (pt)
EP (1) EP3503905A1 (pt)
KR (1) KR102395835B1 (pt)
CN (1) CN109562139A (pt)
AR (1) AR109386A1 (pt)
BR (1) BR112019003673A2 (pt)
CA (1) CA3029456A1 (pt)
MA (1) MA46034A (pt)
MX (1) MX2019001854A (pt)
RU (1) RU2748417C2 (pt)
TW (1) TW201811311A (pt)
WO (1) WO2018036819A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114159546A (zh) * 2021-12-20 2022-03-11 双鹤药业(海南)有限责任公司 新一代合成肺表面活性物质制剂及其临床应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260273A (en) 1988-01-06 1993-11-09 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
CA2063273C (en) * 1989-07-11 2002-09-24 Bradley J. Benson Surfactant compositions and methods
EP0976403A1 (en) * 1998-07-30 2000-02-02 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Adjuvant comprising pulmonary surfactant
CA2372558A1 (en) 1999-06-11 2000-12-21 Byk Gulden Lomberg Chemische Fabrik Gmbh Pharmaceutical preparation containing modifications of surfactant protein b (sp-b) and surfactant protein c (sp-c)
ATE252887T1 (de) * 1999-09-24 2003-11-15 Alcon Inc Topische suspensionsformulierungen enthaltend ciprofloxacin und dexamethason
US20050031706A1 (en) * 2003-08-06 2005-02-10 Pena Lorraine E. Viscosity-stable compositions useful for treating gastrointestinal disorders
WO2008011559A2 (en) 2006-07-20 2008-01-24 University Of Rochester Synthetic lung surfactant and use thereof
DK2078038T3 (da) * 2006-10-13 2013-12-02 Chiesi Farma Spa Rekonstituerede surfaktanter med forbedrede egenskaber
US8399406B2 (en) * 2009-06-05 2013-03-19 Chiesi Farmaceutici S.P.A. Reconstituted surfactant composition containing analogs of surfactant protein B (SP-B) and surfactant protein C (SP-C)
CN102049040A (zh) * 2009-10-30 2011-05-11 北京隆旗生物科技有限公司 人工表面活性物质混合液及其制备与应用
ES2644317T3 (es) * 2012-11-21 2017-11-28 Chiesi Farmaceutici S.P.A. Tensioactivos pulmonares reconstituidos
US10738079B2 (en) * 2017-04-14 2020-08-11 Emory University Compositions and methods for managing respiratory conditions

Also Published As

Publication number Publication date
CA3029456A1 (en) 2018-03-01
US10543256B2 (en) 2020-01-28
KR20190039933A (ko) 2019-04-16
EP3503905A1 (en) 2019-07-03
RU2019107379A3 (pt) 2020-11-23
MX2019001854A (es) 2019-11-11
AR109386A1 (es) 2018-11-28
WO2018036819A1 (en) 2018-03-01
MA46034A (fr) 2021-04-28
RU2019107379A (ru) 2020-09-25
US20180055914A1 (en) 2018-03-01
RU2748417C2 (ru) 2021-05-25
CN109562139A (zh) 2019-04-02
KR102395835B1 (ko) 2022-05-10
TW201811311A (zh) 2018-04-01

Similar Documents

Publication Publication Date Title
BR112019003173A2 (pt) formulação farmacêutica, uso de uma formulação farmacêutica e método para evitar o aumento da viscosidade durante o armazenamento de uma formulação farmacêutica
BR112018005316A2 (pt) ?uso de lisina para restabelecer/aumentar a atividade antibacteriana na presença de surfactante pulmonar de antibióticos inibidos desse modo?
BR112016022598A8 (pt) composição aerossol farmacêutica na forma de um pó seco para liberação pulmonar, forma de dosagem unitária, pacote farmacêutico, kit e uso
GT201700150A (es) Derivados de glucagón con estabilidad mejorada
MX2018013490A (es) Derivados aromaticos de sulfonamida.
CR20170242A (es) Benzamidas sustituidas copn 1,3-tiazol-2-ilo
WO2014194254A9 (en) Treatment of cancers using pi3 kinase isoform modulators
BR112017004524A2 (pt) pirrolopirimidinas para uso na infecção pelo vírus da gripe
CL2016001543A1 (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas.
PH12015502013B1 (en) Pharmaceutical composition of s-ketamine hydrochloride
MX2018011100A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
PH12015501957A1 (en) Pharmaceutical composition of s-ketamine hydrochloride
BR112018000592A2 (pt) composição de desbloqueio de nariz congestionado tendo atividade antiviral
CO6400190A2 (es) Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma
BR112017006842A2 (pt) formulação de rapamicina inalável para o tratamento de hipertensão pulmonar
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
BR112016025126A2 (pt) formulação líquida compreendendo composto neutralizante de gm-csf
WO2015171460A3 (en) Formulations of cyclophosphamide liquid concentrate
BR112014016472A8 (pt) formulação farmacêutica estável para administração oral que compreende levocetirizina ou um sal farmaceuticamente aceitável da mesma e montelukast ou um sal farmaceuticamente aceitável do mesmo
BR112019003673A2 (pt) formulação farmacêutica, uso de uma formulação farmacêutica e método para evitar o aumento da viscosidade durante o armazenamento de uma formulação farmacêutica
MX2019010218A (es) Derivados de pirazol como inhibidores de bromodominio.
BR112015020307A2 (pt) formulação de cápsula rígida
UA117200C2 (uk) Водні фармацевтичні композиції для місцевого застосування у ротовій порожнині, що містять флурбіпрофен і декспантенол
Mayet et al. Electronic cigarettes: harm reduction tool or new substance use behavior?
PE20210927A1 (es) Composiciones antimicrobianas con agentes efervescentes

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]